AbbVie M25-268 – IPF

  • Study Sponsor and Protocol Number: 
    AbbVie M25-268
  • Specialty:
    Pulmonology
  • Type:
    Investigational Drug
  • Inclusion:
    >40 years of age
    Diagnosed with IPF based on chest high-resolution Computed Tomography (HRCT)
    Either stable treatment with antifibrotics for at least 8 weeks prior to screening visit or not treated with antifibrotics for at least 4 weeks prior to screening visit
    Must be able to complete a Six-Minute Walk Test assessment (ambulatory)
  • Exclusion:

    • Acute IPF exacerbation diagnosis within 4 months prior to screening for the trial
    Lower respiratory tract infection within 4 weeks before screening for the trial